Continuous infusion of beta-lactam antibiotics in severe infections: a review of its role.
about
Antibiotic dosing in the 'at risk' critically ill patient: Linking pathophysiology with pharmacokinetics/pharmacodynamics in sepsis and trauma patients.Clinical outcomes with alternative dosing strategies for piperacillin/tazobactam: a systematic review and meta-analysis.Continuous beta-lactam infusion in critically ill patients: the clinical evidenceTreatment with tigecycline of recurrent urosepsis caused by extended-spectrum-beta-lactamase-producing Escherichia coli.Clinical and microbiological efficacy of continuous versus intermittent application of meropenem in critically ill patients: a randomized open-label controlled trial.Pharmacokinetics and pharmacodynamics of antibacterial agents.Population pharmacokinetics of ceftazidime in intensive care unit patients: influence of glomerular filtration rate, mechanical ventilation, and reason for admission.Pharmacokinetics of ertapenem in critically ill patients receiving continuous venovenous hemodialysis or hemodiafiltration.Improved outcomes of patients with end-stage cystic fibrosis requiring invasive mechanical ventilation for acute respiratory failure.Ceftazidime for respiratory infections.Antimicrobial treatment of febrile neutropenia: pharmacokinetic-pharmacodynamic considerations.Clinical implications of antibiotic pharmacokinetic principles in the critically ill.Evaluating outcomes of alternative dosing strategies for cefepime: a qualitative systematic review.Continuous and Prolonged Intravenous β-Lactam Dosing: Implications for the Clinical Laboratory.Immediate outcomes of bacterial meningitis in childhood may benefit from slow initial β-lactam infusion and oral paracetamol.Hospital Length of Stay Among Patients Receiving Intermittent Versus Prolonged Piperacillin/Tazobactam Infusion in the Intensive Care Units.Pharmacokinetic/pharmacodynamic target attainment of intravenous β-lactam regimens against Gram-negative bacteria isolated in a Brazilian teaching hospital.Continuous versus intermittent piperacillin/tazobactam infusion in infection due to or suspected pseudomonas aeruginosa.Osteoarticular infection caused by MDR Pseudomonas aeruginosa: the benefits of combination therapy with colistin plus β-lactams.Ceftazidime dosage regimen in intensive care unit patients: from a population pharmacokinetic approach to clinical practice via Monte Carlo simulationsIs there a role for continuous infusion of β-lactam antibiotics in severe sepsis?Pharmacokinetics of a continuous rate infusion of ceftiofur sodium in normal foals.Pharmacokinetic/pharmacodynamic relationship of cefquinome against Pasteurella multocida in a tissue-cage model in yellow cattle.Meropenem dosing in critically ill patients with sepsis and without renal dysfunction: intermittent bolus versus continuous administration? Monte Carlo dosing simulations and subcutaneous tissue distribution.Risk factors for target non-attainment during empirical treatment with β-lactam antibiotics in critically ill patients.The development and evaluation of a subcutaneous infusion delivery system based on osmotic pump control and gas drive.Opportunistic infections in end stage liver disease.Antimicrobial Agents
P2860
Q33824276-606ED78D-D92C-4F72-A448-64D192DFC73CQ34892334-73B8070C-4685-46FC-85C5-14B6D0048055Q36329228-F8480CAF-AF9F-4C51-8DAF-197753B0B4C3Q36452576-FD77537F-066D-411B-99E4-AE45D36F3605Q36633761-75849EDC-8EC7-4A46-8724-D8A920EDC6DCQ36911111-DE527B13-5382-4062-B665-6B3F4E530A25Q37392874-30620749-7BC1-4BAD-9B45-5CB9D0546A2CQ37643628-29FDFD50-BBCF-45C1-9C0D-E6F47661616EQ37909115-58D55F0A-44E5-455E-81D7-A4940FE43E9FQ38040144-44F53425-157E-47E7-802C-119F6B60E18AQ38117578-9AC94DC5-8C1A-49CE-B99A-A1F3CE4ED6F9Q38138835-74F869CD-F7D2-450B-9A90-388B1BA662D7Q38313276-FDABFF35-2218-4D6A-BD7D-336F415F1738Q38896040-AE0C4A3E-96E5-4C83-96B3-A2A50B8E6A3AQ39696732-110605CC-9915-4E86-9700-ED1A648C02F9Q40219976-C018FE70-F08D-4F86-81CE-64425BB77F52Q40375664-439F399A-AD4C-4E55-B308-7A4A8C098532Q40948657-5A7901FF-0E4A-4D88-A441-5A7C78914CE7Q40975034-2A179653-2B3C-46D4-859F-618A983BE420Q42006135-16650E84-6414-4674-93CC-245DCD19574FQ42751350-69F9E5FE-EBF8-4E4D-99CC-E289DD6DE56FQ44975714-E4DCBCE6-D7CC-4BA2-A030-2D6168F5FEE1Q45723481-64008E87-761C-41F9-AF44-0C6552F27B17Q46034494-01A972AB-5EE4-4EC7-AD2B-DF4548F18ED2Q49056677-186E97F3-9686-413A-B62D-D9112CF42B61Q50570377-6BB7873C-177C-4E72-A4B4-9D34E07C0746Q53688643-926C1573-501E-42BD-BBE6-82B5F1D64472Q57549163-D661E773-8DA4-4C20-A60D-0475438D9355
P2860
Continuous infusion of beta-lactam antibiotics in severe infections: a review of its role.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Continuous infusion of beta-la ...... ections: a review of its role.
@ast
Continuous infusion of beta-la ...... ections: a review of its role.
@en
type
label
Continuous infusion of beta-la ...... ections: a review of its role.
@ast
Continuous infusion of beta-la ...... ections: a review of its role.
@en
prefLabel
Continuous infusion of beta-la ...... ections: a review of its role.
@ast
Continuous infusion of beta-la ...... ections: a review of its role.
@en
P2093
P1476
Continuous infusion of beta-la ...... ections: a review of its role.
@en
P2093
Elizabeth Paratz
Jennifer Paratz
Wolfgang A Krueger
P356
10.1016/J.IJANTIMICAG.2007.02.002
P577
2007-04-17T00:00:00Z